Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P&T. 2011;36(4):197-202.
Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1-17. doi:10.1128/CMR.16.1.1-17.2003
Cao M, Fan J, Lu L, et al. Long term outcome of prevention of liver cancer by hepatitis B vaccine: Results from an RCT with 37 years. Cancer Lett. 2022;536:215652. doi:10.1016/j.canlet.2022.215652
Jiang S, Redelman-Sidi G. BCG in bladder cancer immunotherapy. Cancers (Basel). 2022;14(13):3073. Published 2022 Jun 23. doi:10.3390/cancers14133073
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422. doi:10.1056/NEJMoa1001294
Karikó K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833-1840. doi:10.1038/mt.2008.200
Karikó K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem. 2004;279(13):12542-12550. doi:10.1074/jbc.M310175200
Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28. Published 2022 Mar 18. doi:10.1186/s13045-022-01247-x
Patel R, Kaki M, Potluri VS, Kahar P, Khanna D. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. Hum Vaccin Immunother. 2022;18(1):2002083. doi:10.1080/21645515.2021.2002083
Romano' L, Zanetti AR. Hepatitis B Vaccination: A historical overview with a focus on the Italian achievements. Viruses. 2022;14(7):1515. Published 2022 Jul 11. doi:10.3390/v14071515
Saleh A, Qamar S, Tekin A, Singh R, Kashyap R. Vaccine development throughout history. Cureus. 2021;13(7):e16635. Published 2021 Jul 26. doi:10.7759/cureus.16635
Wang B, Pei J, Xu S, Liu J, Yu J. Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities. Front Immunol. 2023;14:1246682. Published 2023 Sep 6. doi:10.3389/fimmu.2023.1246682